Загрузка...
Sodium‐glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus
BACKGROUND: Sodium‐glucose cotransporter (SGLT) 2 inhibitors were recently approved as glucose‐lowering interventions in people with type 2 diabetes mellitus (T2DM). Potential beneficial or harmful effects of SGLT 2 inhibitors in people at risk for the development of T2DM are unknown. OBJECTIVES: To...
Сохранить в:
| Опубликовано в: : | Cochrane Database Syst Rev |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons, Ltd
2016
|
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6486006/ https://ncbi.nlm.nih.gov/pubmed/27101360 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012106.pub2 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|